$CELG GED-0301 for Crohn’s Disease Show Encouraging Results
Results from a Phase 1 b trial evaluating Celgene�s $CELG GED-0301 in patients with active Crohn�s disease demonstrated a clinical response rate of 67% and a remission rate of 48%. The data was being...
View ArticleBiotech Trade Alerts Archive -2016-10-17- $LPCN, $PTCT, $OMER, $CELG, $TEVA
DRKKD.com Real Time Biotech Trade Alert Service October 17, 2016. Tickers covered: LPCN, PTCT, OMER, CELG, TEVA
View ArticleNHS Issues Positive appraisal for $CELG’s Otezla
England�s National Institute for Health and Care Excellence (NICE), an advisory group to the National Health Service (NHS) on costs and quality, issued a positive final appraisal determination...
View ArticleBiotech Trade Alerts Archive -2016-10-21- $RIGL, $TEVA, $TBPH, $CELG, $PBYI,...
DRKKD.com Real Time Biotech Trade Alert Service April 1, 2016. Tickers covered: RIGL, TEVA, TBPH, CELG, PBYI, RHHBY
View ArticleThe three ‘Gens and Gilead $GILD $CELG $BIIB $AMGN: Which has the most promise?
There are others, but these four companies - Celgene $CELG Biogen $BIIB Amgen $AMGN and Gilead $GILD - have often been discussed in these forums. These are a special subset of biotech companies, those...
View ArticleCelgene ($CELG) receives positive recommendation for Otezla
Celgene ($CELG) reported receiving the recommendation from England's National Institute for Health and Care Excellence (NICE) for the use of its OTEZLA (apremilast) for treating adult patients with...
View Article
